BACKGROUND AND OBJECTIVES: Primary prevention of disordered mineral metabolism in CKD necessitates knowledge of its early pathophysiology. This study evaluated daily fluctuations in mineral metabolites in patients with CKD stages 3 and 4 before and after short-term calcitriol treatment and tested the effects of dietary calcium and calcitriol supplementation on these parameters in the dynamic postprandial setting. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Twelve CKD patients received calcitriol (0.25 μg daily for 1 week) with hourly assessments of mineral metabolites made throughout the day and in the context of standardized meals before and after treatment. Calcium content (250 versus 500 mg) in the breakfasts constituted the dietary calcium intervention. Twelve healthy volunteers were used as controls. RESULTS: At baseline, compared with controls, fasting CKD subjects had higher parathyroid hormone and fibroblast growth factor 23 levels and greater fractional excretion of phosphate. After breakfast, urinary calcium excretion increased and parathyroid hormone levels dipped transiently in both groups, but they rose soon thereafter, reaching higher peaks in CKD. Calcitriol decreased fasting parathyroid hormone levels, and when combined with dietary calcium load, it normalized the postprandial parathyroid and calcemic responses. Daily variability in mineral metabolites was preserved in CKD before and after calcitriol. Fibroblast growth factor 23 levels increased after calcitriol, although the response was heterogeneous. CONCLUSIONS: Short-term treatment with calcitriol and dietary calcium supplementation normalizes the parathyroid and calcemic postprandial responses in patients with CKD, in whom the diurnal rhythms of mineral metabolites are preserved. Future studies should investigate the variable fibroblast growth factor 23 response to calcitriol in CKD.
BACKGROUND AND OBJECTIVES: Primary prevention of disordered mineral metabolism in CKD necessitates knowledge of its early pathophysiology. This study evaluated daily fluctuations in mineral metabolites in patients with CKD stages 3 and 4 before and after short-term calcitriol treatment and tested the effects of dietary calcium and calcitriol supplementation on these parameters in the dynamic postprandial setting. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Twelve CKD patients received calcitriol (0.25 μg daily for 1 week) with hourly assessments of mineral metabolites made throughout the day and in the context of standardized meals before and after treatment. Calcium content (250 versus 500 mg) in the breakfasts constituted the dietary calcium intervention. Twelve healthy volunteers were used as controls. RESULTS: At baseline, compared with controls, fasting CKD subjects had higher parathyroid hormone and fibroblast growth factor 23 levels and greater fractional excretion of phosphate. After breakfast, urinary calcium excretion increased and parathyroid hormone levels dipped transiently in both groups, but they rose soon thereafter, reaching higher peaks in CKD. Calcitriol decreased fasting parathyroid hormone levels, and when combined with dietary calcium load, it normalized the postprandial parathyroid and calcemic responses. Daily variability in mineral metabolites was preserved in CKD before and after calcitriol. Fibroblast growth factor 23 levels increased after calcitriol, although the response was heterogeneous. CONCLUSIONS: Short-term treatment with calcitriol and dietary calcium supplementation normalizes the parathyroid and calcemic postprandial responses in patients with CKD, in whom the diurnal rhythms of mineral metabolites are preserved. Future studies should investigate the variable fibroblast growth factor 23 response to calcitriol in CKD.
Authors: G el-Hajj Fuleihan; E B Klerman; E N Brown; Y Choe; E M Brown; C A Czeisler Journal: J Clin Endocrinol Metab Date: 1997-01 Impact factor: 5.958
Authors: M S Stein; S C Scherer; S L Walton; R E Gilbert; P R Ebeling; L Flicker; J D Wark Journal: Clin Endocrinol (Oxf) Date: 1996-04 Impact factor: 3.478
Authors: Sven-Jean Tan; Edward R Smith; Michael M X Cai; Stephen G Holt; Tim D Hewitson; Nigel D Toussaint Journal: Int Urol Nephrol Date: 2015-11-14 Impact factor: 2.370
Authors: Joachim H Ix; Cheryl A M Anderson; Gerard Smits; Martha S Persky; Geoffrey A Block Journal: Am J Clin Nutr Date: 2014-08-27 Impact factor: 7.045
Authors: Tamara Isakova; Joachim H Ix; Stuart M Sprague; Kalani L Raphael; Linda Fried; Jennifer J Gassman; Dominic Raj; Alfred K Cheung; John W Kusek; Michael F Flessner; Myles Wolf; Geoffrey A Block Journal: J Am Soc Nephrol Date: 2015-05-12 Impact factor: 10.121
Authors: Tamara Isakova; Jessica Houston; Laura Santacruz; Eva Schiavenato; Gabriel Somarriba; William G Harmon; Steven E Lipshultz; Tracie L Miller; Paolo G Rusconi Journal: Pediatr Nephrol Date: 2013-06-06 Impact factor: 3.714
Authors: Pamela L Lutsey; Christina M Parrinello; Jeffrey R Misialek; Andy N Hoofnagle; Clark M Henderson; Thomas J Laha; Erin D Michos; John H Eckfeldt; Elizabeth Selvin Journal: Clin Chem Date: 2016-09-30 Impact factor: 8.327
Authors: Heather L Palomino; Dena E Rifkin; Cheryl Anderson; Michael H Criqui; Mary A Whooley; Joachim H Ix Journal: Clin J Am Soc Nephrol Date: 2013-03-28 Impact factor: 8.237
Authors: Nao Souma; Tamara Isakova; David Lipiszko; Ralph L Sacco; Mitchell S V Elkind; Janet T DeRosa; Shonni J Silverberg; Armando J Mendez; Chuanhui Dong; Clinton B Wright; Myles Wolf Journal: J Clin Endocrinol Metab Date: 2016-08-08 Impact factor: 5.958